INTRODUCTION

RedCell Therapeutics™ (RTX) is a new class of allogeneic, off-the-shelf cellular therapeutic candidates for the treatment of cancer, rare diseases, and autoimmune diseases.

For the treatment of cancer, RTXs are engineered to mimic human immunology and induce a tumor-specific immune response by expanding tumor-specific T cells against a target antigen in a first-in-human clinical trial. RTX-321 is a candidate for the potential treatment of HPV-positive cancers.

RESULTS AND METHODS

Figure 2. RTX-aAPC is a Cellular Therapy That Drives Antigen-Specific Activation and Proliferation of T Cells

(A) Measurement of cell receptor TCR engagement with E+ TCR-T mLs incubated with RTX-aAPC product candidate, RTX-321, is for the potential treatment of HPV-positive cancers.

Figure 3. 3T4-21 HPV-aAPC Engagement Engages HPV-Specific T Cells and Drives Antigen-Specific T Cell Expansion

(RTX-321) delays E7/E7A2-driven growth in tumor cell lines as compared to 321

OSCA-1 cells were cultured with RCT-OVA-4-1BBL plus RTX-321, mRBC-OVA-4-1BBL, or media alone. The percent killing was calculated by live tumor cell percent of target only or RCT-OVA-4-1BBL+ media only. Data points represent the mean of triplicate samples; error bars represent standard error of the mean.

DISCLOSURES

All authors: Employment and/or ownership in Rubica Therapeutics.